ArticleHereditas2025
Uncovering new MicroRNAs linked to acute pancreatitis: zeroing in on the protective effect.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe microRNA expression profile in the bodily fluids of individuals with acute pancreatitis (AP) undergoes considerable alterations; nevertheless, the precise mechanism requires more elucidation.
methodsA dataset of 2083 human blood microRNAs (miRNAs) was obtained from the miRNA expression quantitative loci data. The genome-wide association study data for AP was obtained from the FinnGen Consortium. The causal association between miRNA and susceptibility to AP was evaluated using the Mendelian randomization (MR) method. Receiver operating characteristic (ROC) curve analyses were implemented to assess the miRNA's clinical usefulness. The GSE188819 and GSE249349 datasets were analyzed to determine changes in cell subset amounts and differentially expressed genes during the advancement and regression of AP mice. We assessed the inhibitory impact of miR-27b-3p and miR-193a-5p overexpression on AR42J cell and RAW 264.7 cell inflammation using western blot.
resultsFollowing a thorough process of genetic variation selection, MR analysis, and sensitivity analysis, we identified 66 miRNAs with suggestive causality to AP susceptibility. We conducted ROC curve analysis on 66 variables, identifying 6 miRNAs that have the potential to diagnose AP. Six and twelve cell subsets were identified from the GSE249349 and GSE188819 datasets, respectively. In the inflammatory advancement stage, the percentage of acinar cells in the AP group decreased relative to the control group samples. In the inflammatory regression phase, the percentage of monocytes in the AP (96 h) group decreased relative to the AP (12 h) group. In vitro, experiments have found that the overexpression of miR-27b-3p and miR-193a-5p in RAW 264.7 cells AR42J cells significantly inhibited the protein expression of p-P65.
conclusionOur research identified novel miRNAs associated with the pathogenesis of AP. In vitro experiments have confirmed that miR-27b-3p and miR-193a-5p can inhibit the inflammatory response in RAW 264.7 cells and AR42J cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.